What is the prognosis of primary central nervous system lymphoma (PCNSL) in immunocompetent patients?

Updated: Jan 19, 2018
  • Author: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print


The initial response to radiation therapy is excellent, often resulting in complete resolution of radiographic abnormalities. Nevertheless, the duration of response is short, and median survival duration with radiation therapy alone averages only 18 months. Relapse in patients with parenchymal disease is usually within the brain, although leptomeningeal, vitreous and, rarely, systemic recurrences are reported.

Methotrexate-based chemotherapy as the sole treatment modality results in median survival duration approaching 48 months.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!